Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Abstract
Iron overloading disorders linked to mutations in ferroportin have diverse phenotypes in vivo, and the effects of mutations on ferroportin in vitro range from loss of function (LOF) to gain of function (GOF) with hepcidin resistance. We reviewed 359 patients with 60 ferroportin variants. Overall, macrophage iron overload and low/normal transferrin saturation (TSAT) segregated with mutations that caused LOF, while GOF mutations were linked to high TSAT and parenchymal iron accumulation. However, the pathogenicity of individual variants is difficult to establish due to the lack of sufficiently reported data, large inter-assay variability of functional studies, and the uncertainty associated with the performance of available in silico prediction models. Since the phenotypes of hepcidin-resistant GOF variants are indistinguishable from the other types of hereditary hemochromatosis (HH), these variants may be categorized as ferroportin-associated HH, while the entity ferroportin disease may be confined to patients with LOF variants. To further improve the management of ferroportin disease, we advocate for a global registry, with standardized clinical analysis and validation of the functional tests preferably performed in human-derived enterocytic and macrophagic cell lines. Moreover, studies are warranted to unravel the definite structure of ferroportin and the indispensable residues that are essential for functionality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The two-dimensional (2D) structure of ferroportin protein adapted from Liu and Wallace [6,56], revealing 12 transmembrane helices and six extracellular and five intracellular segments. All the variants described in this review are shown as hepcidin-resistant (pink), hepcidin-sensitive or neutral (purple) and hepcidin conflicting/uncertain/unknown (red) GOF variants (squares). and hepcidin resistant (light blue), hepcidin sensitive (dark blue), and hepcidin conflicting-uncertain-unknown (green) LOF variants (dots), or non-classified variants (grey asterix).](https://figures.cochat.ai/paper-figures/372b17ce55994870988faf6b6062f0f6/twenty-years-of-ferroportin-disease-a-review-or-an-update-of-published-clinical-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A confluence of human genetics studies and structure-function evaluations have identified key regions of FPN important in hepcidin regulation 7,19-22 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutation of several residues within the intracellular gate leads to FPN loss of function in ferroportin disease, highlighting the importance of the gate in coordinating the conformational steps necessary for iron efflux 19,28 .”
From Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 2×
“To assess co-segregation in multiple affected family members, the simplified method of segregation analysis (SISA) was applied [22,23] and classified according to recent recommendations to define co-segregation to fit the guidelines of the American College of Medical Genetics and Genomics and the Association for Molec…”
MethodHepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 2×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
WHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469 · cited 3×
“For the two-dimensional (2D) model (Figure 3), we adapted the structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used Pharmaceuticals 2019, 12, 132 17 of 29 the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet Another Scie…”
MethodPositional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Increasing the precision of comparative models with YASARA NOVA—a self‐parameterizing force field
Krieger, E., Koraimann, G., & Vriend, G. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10104 · Cited by 1,514 · cited 3×
“For the two-dimensional (2D) model (Figure 3), we adapted the structure constructed by Liu and Wallace [6,56] and for three-dimensional (3D) model (Figure 4), we used Pharmaceuticals 2019, 12, 132 17 of 29 the recently developed model (Bacterial ferroportin, PDB file 5AYN) and homology modeling in the Yet Another Scie…”
MethodMcKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275
A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267 · cited 1×
“Ferroportin is expressed on the enterocytic basolateral membrane and predominantly in intramacrophagic vesicles [108,131], and there are indications that the mode of hepcidin-induced internalization differs in macrophages [120,132].”
BackgroundSerum ferritin: Past, present and future
Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M., & Torti, S. V. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.03.011 · Cited by 879 · cited 1×
“This corroborates the notion that high TSAT facilitates parenchymal iron deposition, which is considered to be more toxic than macrophage iron overload [154].”
BackgroundMuckenthaler, M. U., Galy, B., & Hentze, M. W. (2008) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.28.061807.155521 · Cited by 701
Research works printed but not linked: 4
- 2015, A Pediatric Case Report of Ferroportin Disease, J. Pediatr. Gastroenterol. Nutr., 63, e205
- Relvas, 2009, Novel human pathological mutation: Gene Symbol: SLC40A1; Disease: Haemochromatosis, type IV, Hum. Genet., 125, 338
- Muehlenberg, 2014, [Family with marked hyperferritinemia as a result of hemochromatosis type 4 (ferroportin disease)], Z. Gastroenterol., 52, 1075
- Caetano, G., Relvas, L., Bento, C., Silveira, M.P., and Ribeiro, L. (2009, January 7–11). Atypical iron deficiency anemia—Association of two new mutations in ferroportin and TMPRSS6 genes. Proceedings of the International BioIron Society Annual Meeting, Porto, Portugal.
Cited by
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS)
Drew, D., North, R. A., Nagarathinam, K., & Tanabe, M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00983 · Cited by 465
Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · Nature · doi:10.1038/s41586-020-2668-z · Cited by 344
Hemochromatosis classification: update and recommendations by the BIOIRON Society
Girelli, D., Busti, F., Brissot, P., Cabantchik, I., Muckenthaler, M. U., & Porto, G. (2022) · Blood · doi:10.1182/blood.2021011338 · Cited by 187
Structural basis of ion transport and inhibition in ferroportin
Pan, Y., Ren, Z., Gao, S., Shen, J., Wang, L., Xu, Z., Yu, Y., Bachina, P., Zhang, H., Fan, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19458-6 · Cited by 81
Interplay of oxidative stress and antioxidant mechanisms in cancer development and progression
Jomová, K., Alomar, S. Y., Valko, R., Fresser, L., Nepovimová, E., Kuča, K., & Valko, M. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04146-5 · Cited by 130
“Ferroportin is a transmembrane protein that transports iron from the intracellular space to the extracellular environment via the iron chaperone poly (RC)-binding protein 2 (PCBP2), which has been found to have ambiguous functions in a variety of cancers (Vlasveld et al. 2019).”
Ethnic Differences in Iron Status
Kang, W., Barad, A., Clark, A. G., Wang, Y., Xu, L., Gu, Z., & O'Brien, K. O. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab035 · Cited by 77
Genetic iron overload disorders
Corradini, E., Buzzetti, E., & Pietrangelo, A. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100896 · Cited by 69
Revisiting hemochromatosis: genetic vs. phenotypic manifestations
Anderson, G. J., & Bardou‐Jacquet, E. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5512 · Cited by 70
Self-citationIron and platelets: A subtle, under‐recognized relationship
Brissot, É., Troadec, M., Loréal, O., & Brissot, P. (2021) · American Journal of Hematology · doi:10.1002/ajh.26189 · Cited by 65
Iron Availability in Tissue Microenvironment: The Key Role of Ferroportin
Gammella, E., Correnti, M., Cairo, G., & Recalcati, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062986 · Cited by 35
“Mutations in FPN lead to disorders of iron metabolism characterized by substantially diverse phenotypes [41].”
BackgroundHypoferremia of inflammation: Innate host defense against infections
Ganz, T., & Nemeth, E. (2023) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2023.102777 · Cited by 32
Membrane Transporters Involved in Iron Trafficking: Physiological and Pathological Aspects
Pasquadibisceglie, A., di Patti, M. C. B., Musci, G., & Polticelli, F. (2023) · Biomolecules · doi:10.3390/biom13081172 · Cited by 27
“Two distinct phenotypes are observed, where iron overload affects different organs: mainly reticulo-endothelial macrophages with low transferrin saturation (type 4A) or liver hepatocytes with high transferrin saturation (type 4B) [55,56].”
BackgroundWhat’s Important and New in Hemochromatosis?
Brissot, P., & Brissot, É. (2020) · Clinical Hematology International · doi:10.2991/chi.k.200726.001 · Cited by 21
Mechanism of Ca2+ transport by ferroportin
Shen, J., Wilbon, A. S., Zhou, M., & Pan, Y. (2023) · eLife · doi:10.7554/elife.82947 · Cited by 23
“Mutations in Fpn cause hereditary hemochromatosis and ironloading anemias in human (Pietrangelo, 2017; Ganz, 2013; Ginzburg, 2019; Vlasveld et al., 2019).”
BackgroundWang, Y., Protchenko, O. V., Huber, K. D., Shakoury‐Elizeh, M., Ghosh, M. C., & Philpott, C. C. (2023) · Blood · doi:10.1182/blood.2023020504 · Cited by 25
Uguen, K., Ka, C., Collod‐Béroud, G., Tertre, M. L., Guellec, J., Férec, C., Béroud, C., Callebaut, I., & Gac, G. L. (2023) · Human Mutation · doi:10.1155/2023/5162256 · Cited by 20
“Various in silico prediction tools have also been tested but have not yet been found to be very informative [20, 23], probably due to the nonconsideration of the molecular-level e ff ect of missense variants in the context of SLC40A1 3D structures.”
InfluentialElbahnsi, A., Dudás, B., Callebaut, I., Hinzpeter, A., & Miteva, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17121602 · Cited by 20
“The hepcidin–ferroportin interaction is central to many inherited and acquired iron metabolism disorders [130–132].”
Structural basis of ferroportin inhibition by minihepcidin PR73
Wilbon, A. S., Shen, J., Ruchala, P. P., Zhou, M., & Pan, Y. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3001936 · Cited by 17
“Introduction Ferroportin (Fpn) is a Fe/2H antiporter that is highly expressed in enterocytes, hepatocytes, and macrophages to export Fe derived from either dietary intake or digestion of senescent red blood cells (Ganz, 2005; Pan et al., 2020; Vlasveld et al., 2019).”
BackgroundIdentification of Novel Mutations by Targeted NGS Panel in Patients with Hyperferritinemia
Ravasi, G., Pelucchi, S., Bertola, F., Capelletti, M. M., Mariani, R., & Piperno, A. (2021) · Genes · doi:10.3390/genes12111778 · Cited by 14
“Multiple mutations in SLC40A1 gene have been described so far [6,7,27]: loss‐of‐func‐ tion variants are characterized by diminished cell surface expression, lower iron export capacity, and hyperferritinemia with normal TSAT (Ferroportin disease), while gain‐of‐ function variants are characterized by ferroportin resist…”
BackgroundUguen, K., Tertre, M. L., Tchernitchko, D., Elbahnsi, A., Maestri, S., Gourlaouen, I., Férec, C., Ka, C., Callebaut, I., & Gac, G. L. (2024) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2024.100335 · Cited by 15
Hoving, V., Donker, A. E., Schols, S. E. M., & Swinkels, D. W. (2025) · British Journal of Haematology · doi:10.1111/bjh.20030 · Cited by 16
“49 Although the long-term effects of such iron accumulation remain unclear, patients with (loss- of-function) ferroportin disease, who have similar biochemical profiles, typically do not experience severe complications despite excessive high ferritin levels.”
Self-citationIron as Therapeutic Target in Human Diseases
Gozzelino, R., Poli, M., & Arosio, P. (2019) · Pharmaceuticals · doi:10.3390/ph12040178 · Cited by 10
Baas, F. S., Rishi, G., Swinkels, D. W., & Subramaniam, V. N. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab130 · Cited by 11
Self-citationA simple clinical score to promote and enhance ferroportin disease screening
Landemaine, A., Hamdi‐Rozé, H., Cunat, S., Loustaud-Ratti, V., Causse, X., Ahmed, S. N. S., Drénou, B., Bureau, C., Pelletier, G., de Kerguenec, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.022 · Cited by 10
Self-citationTertre, M. L., Ka, C., Raud, L., Berlivet, I., Gourlaouen, I., Richard, G., Uguen, K., Chen, J., Férec, C., Fichou, Y., et al. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102527 · Cited by 13
Honma, Y., Karasuyama, T., Kumamoto, K., Shimajiri, S., Toki, Y., Tatsumi, Y., Sumida, K., Koikawa, K., Morino, K., Oe, S., et al. (2020) · Medical Molecular Morphology · doi:10.1007/s00795-020-00259-1 · Cited by 7
Iron chelators reverse organ damage in type 4B hereditary hemochromatosis
Wu, L., Song, Z., Li, Q., Mou, L.-J., Yu, Y., Shen, S., & Song, X. (2021) · Medicine · doi:10.1097/md.0000000000025258 · Cited by 8
Tertre, M. L., Elbahnsi, A., Ged, C., Uguen, K., Gourlaouen, I., Férec, C., Ka, C., Gac, G. L., & Callebaut, I. (2025) · The FASEB Journal · doi:10.1096/fj.202500790rr · Cited by 5
“There may be differences in the evaluation of FPN1 mutants across various cell types, particularly between HEK293T and macrophage-derived cells compared to enterocyte-derived cells [46].”
Production of Recombinant Human Ceruloplasmin: Improvements and Perspectives
di Patti, M. C. B., Cutone, A., Nemčovič, M., Pakanová, Z., Baráth, P., & Musci, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158228 · Cited by 5
Leischner, C., Marongiu, L., Piotrowsky, A., Niessner, H., Venturelli, S., Burkard, M., & Renner, O. (2023) · Antioxidants · doi:10.3390/antiox12040916 · Cited by 7
The Ferroxidase–Permease System for Transport of Iron Across Membranes: From Yeast to Humans
Amadei, M., Polticelli, F., Musci, G., & di Patti, M. C. B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030875 · Cited by 5
“Mutations causing replacement of Fpn key residues involved in iron binding and transport, and in ubiquitination and internalization of the transporter are found in patients affected by type 4 haemochromatosis, an iron overload pathology [106,107].”
Does phlebotomy in people with haemochromatosis become history?
Swinkels, D. W., & Matlung, H. L. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00283-2 · Cited by 6
Self-citationTroppmair, M. R., Ricci, A., Scarlini, S., Pelucchi, S., Porto, G., Busti, F., Sánchez, M., Weißensteiner, H., Schönherr, S., Forer, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.016 · Cited by 5
Self-citationIron Metabolism and Related Disorders
Ginzburg, Y. Z., & Finberg, K. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00012-1 · Cited by 4
Amadei, M., Niro, A., Fullone, M. R., Miele, R., Polticelli, F., Musci, G., & di Patti, M. C. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511919 · Cited by 4
Glucose induced regulation of iron transporters implicates kidney iron accumulation
Kumar, R., Kulshreshtha, D., Aggarwal, A., Asthana, S., Dinda, A. K., & Mukhopadhyay, C. K. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130713 · Cited by 3
Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models
Weidle, U. H., & Nopora, A. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20192 · Cited by 3
RNF217: brokering ferroportin degradation
Parrow, N. L., & Fleming, R. E. (2021) · Blood · doi:10.1182/blood.2021011496 · Cited by 3
Hepcidin: A multifaceted hormone in iron homeostasis and tumor biology
Liu, X., Zhang, X., Fan, Y., & Tan, K. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.10.003 · Cited by 3
Amadei, M., Lauro, A. D., Polticelli, F., Musci, G., & di Patti, M. C. B. (2025) · BioMetals · doi:10.1007/s10534-025-00725-2 · Cited by 2
“Missense mutations of Fpn cause type 4 hereditary hemochromatosis, a dominant form of hemochromatosis with parenchymal and/or reticulo-endothelial iron overload (Pietrangelo 2017; Vlasveld et al. 2019; Uguen et al. 2023).”
Serum concentration of ferroportin in women of reproductive age
Ljubić, K., Penava, N., Tomić, V., Cvetković, I., Pušić, A., Mikulić, V., Mikulić, I., Ćuk, A., & Rumora, L. (2024) · Biochemia Medica · doi:10.11613/bm.2024.030701 · Cited by 3
HFE-Related Hemochromatosis May Be a Primary Kupffer Cell Disease
Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2025) · Biomedicines · doi:10.3390/biomedicines13030683 · Cited by 3
“Gain-of-function mutations on the other hand, make ferroportin resistant to hepcidin leading to a similar impairment of the hepcidin– ferroportin axis, as found in type 1-3 HH, with high transferrin saturation, and iron loading of hepatocytes [267–269].”
Structure of human ferroportin bound to hepcidin reveals mechanisms of iron homeostasisPreprint
Billesbølle, C. B., Azumaya, C. M., Kretsch, R. C., Powers, A. S., Gonen, S., Schneider, S., Arvedson, T., Dror, R. O., Cheng, Y., & Manglik, A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.16.993006 · Cited by 3
Womack, J., Sukumaran, A., Li, X., Lozovatsky, L., Gallagher, P. G., Seid, J. E., & Finberg, K. E. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102532 · Cited by 1
“Mutations that impair iron export function result in the classical ferroportin disease phenotype characterized by hyperferritinemia, normal transferrin saturation, and macrophage iron loading, and mutations that impair the regulation of ferroportin by hepcidin result in a non-classical form of the disease exhibiting h…”
BackgroundFábrega, E., Sánchez, Á. P., Fortea, J. I., Antón, Á., & Crespo, J. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.03.010 · Cited by 1
Hereditary haemochromatosis due to hepcidin resistance
Jensen, M. M., Pedersen, K. B., & Havelund, T. (2025) · Ugeskrift for Læger · doi:10.61409/v12240897 · Cited by 1
Assay developments for detection of biological analytes
Tan, J. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/143757
Iron Metabolism: From Inflammation to Cancer
Paola, A. D., Tortora, C., Argenziano, M., Leva, C. D., & Rossi, F. (2021) · Annals of Hematology & Oncology · doi:10.26420/annhematoloncol.2021.1351
“In human beings systemic iron levels are principally controlled by hepcidin- FPN-1 axis [15], even though genetics and structure-function evaluations are ongoing to better clarify the exact molecular mechanism underlying their interaction [16-18].”
BackgroundKostić, M., & Jones, L. H. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch15
A 70-year-old Woman with Asymptomatic Ferroportin Disease
Ishikawa, T., Tatsumi, Y., Kato, K., Hayashi, Y., Imai, N., Ito, T., Ishizu, Y., Ishigami, M., Nihei, W., Kato, A., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.2392-23
“Patients harboring these variants exhibit IOCs that are phenotypically and biochemically indistinguishable from Hep-deficient HC with heightened TSAT (6, 9, 10).”
BackgroundResultInfluentialJuneja, P., Rashid, N., Qais, F. A., Tanwar, S., Sultan, I., Ahmad, F., & Rehman, S. U. (2024) · IUBMB Life · doi:10.1002/iub.2809
Sánchez, M. (2024) · Revista Sangre · doi:10.24875/sangre.m24000025
Cao, Z., & Huang, J. (2025) · Pracatical anatomic pathology · doi:10.1007/978-3-031-97506-6_4
Intestine-Specific Ferroportin Ablation Rescues from Systemic Iron Overload in Mice
Castillo, C., GIM, S. C. M. M. F. F., & Das, N. K. (2026) · Nutrients · doi:10.3390/nu18020352
“…we observe the expected coordinated intestinal response, including upregulation of the apical iron uptake machinery (DMT1 and Dcytb) and increased basolateral Fpn1 expression, recapitulating the pathophysiologic mechanisms observed in hereditary hemochromatosis and related disorders [13–16 , 44 ].”
Singh, A. K., Khan, A., Anand, M., Singh, P., Kumar, R., Tilak, A. K., & Srivastava, A. (2026) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2026.2651829
“The members of MFS superfamily are known to be secondary active transporters involved in various transport functions including iron transport e.g. by ferroportin 1 (A member of MFS; Vlasveld et al., 2019).”
Makis, A. C., Saougou, I., & Hatzimichael, E. C. (2026) · HemaSphere · doi:10.1002/hem3.70465 · Cited by 1
“35,36 Loss ‐ of ‐ function, or Type 4A, variants impair ferroportin ‐ mediated iron export, producing iron accumulation in macrophages and enterocytes, hyperferritinemia, low ‐ to ‐ normal TSAT, and preserved hepcidin responsiveness.”
InfluentialVulterini, S., di Patti, M. C. B., Musci, G., & Polticelli, F. (2026) · Biomolecules · doi:10.3390/biom16101382
“…(SLC40A1-HC), previously known as hereditary hemochromatosis type 4B, is caused by gain-of-function (GOF) mutations, which affect mostly residues involved in the binding of hepcidin and are associated with iron overload in liver hepatocytes, a high TSAT, and high ferritin levels [26,27].”
Influential
Metadata
- Authors
- Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W.
- Affiliations
- Bronovo Hospital (NL)
- Radboud University Medical Center (NL)
- Liver Diseases Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
- Molecular Genetics Department, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital Pontchaillou, 35033 Rennes, France
- University of Oxford (GB)
- Corresponding author
- Swinkels, Dorine W.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-09-09
- Volume
- 12
- Issue
- 3
- Pages
- 132
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789780
- OpenAlex
- W2972637634
- Cited by
- 57
- References
- 150
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 9 · 2022: 1 · 2021: 14 · 2020: 9 · 2019: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MC_UU_00008/10)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- ferroportin disease, iron overload, hereditary hemochromatosis, loss-of-function mutations, gain-of-function mutations, transferrin saturation, variant pathogenicity, functional assays, in silico prediction models, patient registry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.